APO Research
Talk to an analyst

APO RESEARCH · REPORT

Anticancer Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Anticancer Drugs Market Outlook and Growth Opportunities 2026

23 December 2025209 pages

Choose your research edition.

Industry ResearchAnticancer Drugs Industry Research Report 2026140 pages · $2,950 USDIndustry Growth & TrendsGlobal Anticancer Drugs Industry Growth and Trends Forecast to 2032120 pages · $3,450 USDMarket StructureGlobal Anticancer Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Anticancer Drugs Market Outlook and Growth Opportunities 2026209 pages · $4,250 USDMarket Analysis & ForecastGlobal Anticancer Drugs Market Analysis and Forecast 2026-2032202 pages · $4,950 USD

Market perspective

The global Anticancer Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Anticancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Anticancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Anticancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Anticancer Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Anticancer Drugs market include Takeda, Johnson & Johnson, Novartis, Merck KGaA, Roche, Eli Lilly, Gilead Sciences, Pfizer and Hengrui Medicine, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Anticancer Drugs market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Anticancer Drugs and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Anticancer Drugs revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Anticancer Drugs market.

Anticancer Drugs Segment by Company

Takeda

Johnson & Johnson

Novartis

Merck KGaA

Roche

Eli Lilly

Gilead Sciences

Pfizer

Hengrui Medicine

GSK

Bristol-Myers Squibb

Amgen

AbbVie

AstraZeneca

Seagen

Regeneron

Ono Pharmaceutical

Merck & Co

Innovent

Exelixis

Anticancer Drugs Segment by Type

Cancer Immunotherapy

Chemotherapy

Targeted Therapy

Other

Anticancer Drugs Segment by Application

Blood-related Cancer

Breast Cancer

Prostate Cancer

Lung Cancer

Other

Anticancer Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Anticancer Drugs status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Anticancer Drugs key companies, revenue, market share, and recent developments.

3. To split the Anticancer Drugs breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Anticancer Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Anticancer Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Anticancer Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anticancer Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Anticancer Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anticancer Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Anticancer Drugs industry.

Chapter 3: Detailed analysis of Anticancer Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Anticancer Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Anticancer Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Anticancer Drugs Industry Trends Table 2. Anticancer Drugs Industry Drivers Table 3. Anticancer Drugs Industry Opportunities and Challenges Table 4. Anticancer Drugs Industry Restraints Table 5. Global Anticancer Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Anticancer Drugs Revenue Share by Company (2021-2026) Table 7. Global Anticancer Drugs Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Anticancer Drugs Key Company Manufacturing Base & Headquarters Table 9. Global Anticancer Drugs Company, Product Type & Application Table 10. Global Anticancer Drugs Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Anticancer Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Cancer Immunotherapy Table 15. Significant Companies of Chemotherapy Table 16. Significant Companies of Targeted Therapy Table 17. Significant Companies of Other Table 18. Global Anticancer Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Anticancer Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Anticancer Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Anticancer Drugs Sales Value Share by Type (2021-2026) Table 22. Global Anticancer Drugs Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Blood-related Cancer Table 24. Significant Companies of Breast Cancer Table 25. Significant Companies of Prostate Cancer Table 26. Significant Companies of Lung Cancer Table 27. Significant Companies of Other Table 28. Global Anticancer Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Anticancer Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 30. Global Anticancer Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 31. Global Anticancer Drugs Sales Value Share by Application (2021-2026) Table 32. Global Anticancer Drugs Sales Value Share by Application (2027-2032) Table 33. Global Anticancer Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Anticancer Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 35. Global Anticancer Drugs Sales Value Share by Region (2021-2026) Table 36. Global Anticancer Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 37. Global Anticancer Drugs Sales Value Share by Region (2027-2032) Table 38. Global Anticancer Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Anticancer Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 40. Global Anticancer Drugs Sales Value Market Share by Country (2021-2026) Table 41. Global Anticancer Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 42. Global Anticancer Drugs Sales Value Market Share by Country (2027-2032) Table 43. Takeda Company Information Table 44. Takeda Business Overview Table 45. Takeda Anticancer Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. Takeda Anticancer Drugs Product Portfolio Table 47. Takeda Recent Development Table 48. Johnson & Johnson Company Information Table 49. Johnson & Johnson Business Overview Table 50. Johnson & Johnson Anticancer Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. Johnson & Johnson Anticancer Drugs Product Portfolio Table 52. Johnson & Johnson Recent Development Table 53. Novartis Company Information Table 54. Novartis Business Overview Table 55. Novartis Anticancer Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. Novartis Anticancer Drugs Product Portfolio Table 57. Novartis Recent Development Table 58. Merck KGaA Company Information Table 59. Merck KGaA Business Overview Table 60. Merck KGaA Anticancer Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. Merck KGaA Anticancer Drugs Product Portfolio Table 62. Merck KGaA Recent Development Table 63. Roche Company Information Table 64. Roche Business Overview Table 65. Roche Anticancer Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Roche Anticancer Drugs Product Portfolio Table 67. Roche Recent Development Table 68. Eli Lilly Company Information Table 69. Eli Lilly Business Overview Table 70. Eli Lilly Anticancer Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Eli Lilly Anticancer Drugs Product Portfolio Table 72. Eli Lilly Recent Development Table 73. Gilead Sciences Company Information Table 74. Gilead Sciences Business Overview Table 75. Gilead Sciences Anticancer Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Gilead Sciences Anticancer Drugs Product Portfolio Table 77. Gilead Sciences Recent Development Table 78. Pfizer Company Information Table 79. Pfizer Business Overview Table 80. Pfizer Anticancer Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Pfizer Anticancer Drugs Product Portfolio Table 82. Pfizer Recent Development Table 83. Hengrui Medicine Company Information Table 84. Hengrui Medicine Business Overview Table 85. Hengrui Medicine Anticancer Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Hengrui Medicine Anticancer Drugs Product Portfolio Table 87. Hengrui Medicine Recent Development Table 88. GSK Company Information Table 89. GSK Business Overview Table 90. GSK Anticancer Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. GSK Anticancer Drugs Product Portfolio Table 92. GSK Recent Development Table 93. Bristol-Myers Squibb Company Information Table 94. Bristol-Myers Squibb Business Overview Table 95. Bristol-Myers Squibb Anticancer Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 96. Bristol-Myers Squibb Anticancer Drugs Product Portfolio Table 97. Bristol-Myers Squibb Recent Development Table 98. Amgen Company Information Table 99. Amgen Business Overview Table 100. Amgen Anticancer Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 101. Amgen Anticancer Drugs Product Portfolio Table 102. Amgen Recent Development Table 103. AbbVie Company Information Table 104. AbbVie Business Overview Table 105. AbbVie Anticancer Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 106. AbbVie Anticancer Drugs Product Portfolio Table 107. AbbVie Recent Development Table 108. AstraZeneca Company Information Table 109. AstraZeneca Business Overview Table 110. AstraZeneca Anticancer Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 111. AstraZeneca Anticancer Drugs Product Portfolio Table 112. AstraZeneca Recent Development Table 113. Seagen Company Information Table 114. Seagen Business Overview Table 115. Seagen Anticancer Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 116. Seagen Anticancer Drugs Product Portfolio Table 117. Seagen Recent Development Table 118. Regeneron Company Information Table 119. Regeneron Business Overview Table 120. Regeneron Anticancer Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 121. Regeneron Anticancer Drugs Product Portfolio Table 122. Regeneron Recent Development Table 123. Ono Pharmaceutical Company Information Table 124. Ono Pharmaceutical Business Overview Table 125. Ono Pharmaceutical Anticancer Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 126. Ono Pharmaceutical Anticancer Drugs Product Portfolio Table 127. Ono Pharmaceutical Recent Development Table 128. Merck & Co Company Information Table 129. Merck & Co Business Overview Table 130. Merck & Co Anticancer Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 131. Merck & Co Anticancer Drugs Product Portfolio Table 132. Merck & Co Recent Development Table 133. Innovent Company Information Table 134. Innovent Business Overview Table 135. Innovent Anticancer Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 136. Innovent Anticancer Drugs Product Portfolio Table 137. Innovent Recent Development Table 138. Exelixis Company Information Table 139. Exelixis Business Overview Table 140. Exelixis Anticancer Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 141. Exelixis Anticancer Drugs Product Portfolio Table 142. Exelixis Recent Development Table 143. Research Programs/Design for This Report Table 144. Authors List of This Report Table 145. Secondary Sources Table 146. Primary Sources List of Figures Figure 1. Anticancer Drugs Product Image Figure 2. Global Anticancer Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Anticancer Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Anticancer Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Cancer Immunotherapy Image Figure 8. Chemotherapy Image Figure 9. Targeted Therapy Image Figure 10. Other Image Figure 11. Global Anticancer Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Anticancer Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Anticancer Drugs Sales Value Share by Type (2021-2032) Figure 14. Blood-related Cancer Image Figure 15. Breast Cancer Image Figure 16. Prostate Cancer Image Figure 17. Lung Cancer Image Figure 18. Other Image Figure 19. Global Anticancer Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Anticancer Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 21. Global Anticancer Drugs Sales Value Share by Application (2021-2032) Figure 22. Global Anticancer Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 23. Global Anticancer Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 24. North America Anticancer Drugs Sales Value (2021-2032) & (US$ Million) Figure 25. North America Anticancer Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Europe Anticancer Drugs Sales Value (2021-2032) & (US$ Million) Figure 27. Europe Anticancer Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Asia-Pacific Anticancer Drugs Sales Value (2021-2032) & (US$ Million) Figure 29. Asia-Pacific Anticancer Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 30. South America Anticancer Drugs Sales Value (2021-2032) & (US$ Million) Figure 31. South America Anticancer Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Middle East & Africa Anticancer Drugs Sales Value (2021-2032) & (US$ Million) Figure 33. Middle East & Africa Anticancer Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 34. USA Anticancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. USA Anticancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. USA Anticancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Canada Anticancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Canada Anticancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Canada Anticancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Mexico Anticancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Mexico Anticancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Mexico Anticancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Germany Anticancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Germany Anticancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Germany Anticancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. France Anticancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. France Anticancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. France Anticancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. U.K. Anticancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. U.K. Anticancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. U.K. Anticancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Italy Anticancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Italy Anticancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Italy Anticancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Spain Anticancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Spain Anticancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Spain Anticancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Russia Anticancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Russia Anticancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Russia Anticancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Netherlands Anticancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Netherlands Anticancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Netherlands Anticancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Nordic Countries Anticancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Nordic Countries Anticancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Nordic Countries Anticancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. China Anticancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. China Anticancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. China Anticancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Japan Anticancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Japan Anticancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Japan Anticancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. South Korea Anticancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. South Korea Anticancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. South Korea Anticancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. India Anticancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. India Anticancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. India Anticancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Australia Anticancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Australia Anticancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Australia Anticancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Southeast Asia Anticancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Southeast Asia Anticancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Southeast Asia Anticancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Brazil Anticancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Brazil Anticancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Brazil Anticancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Argentina Anticancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Argentina Anticancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Argentina Anticancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Chile Anticancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Chile Anticancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Chile Anticancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Colombia Anticancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Colombia Anticancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Colombia Anticancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Peru Anticancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Peru Anticancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Peru Anticancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Anticancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Saudi Arabia Anticancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Saudi Arabia Anticancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Israel Anticancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Israel Anticancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Israel Anticancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. UAE Anticancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. UAE Anticancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. UAE Anticancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Turkey Anticancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Turkey Anticancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Turkey Anticancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Iran Anticancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Iran Anticancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Iran Anticancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Egypt Anticancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Egypt Anticancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Egypt Anticancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Years Considered Figure 119. Research Process Figure 120. Key Executives Interviewed

Scope & coverage.

Types
  • Cancer Immunotherapy
  • Chemotherapy
  • Targeted Therapy
  • Other
Applications
  • Blood-related Cancer
  • Breast Cancer
  • Prostate Cancer
  • Lung Cancer
  • Other
Companies covered
  • Takeda
  • Johnson & Johnson
  • Novartis
  • Merck KGaA
  • Roche
  • Eli Lilly
  • Gilead Sciences
  • Pfizer
  • Hengrui Medicine
  • GSK
  • Bristol-Myers Squibb
  • Amgen
  • AbbVie
  • AstraZeneca
  • Seagen
  • Regeneron
  • Ono Pharmaceutical
  • Merck & Co
  • Innovent
  • Exelixis

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Anticancer Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Anticancer Drugs Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Anticancer Drugs Market Dynamics
  1. 2.1 Anticancer Drugs Industry Trends
  2. 2.2 Anticancer Drugs Industry Drivers
  3. 2.3 Anticancer Drugs Industry Opportunities and Challenges
  4. 2.4 Anticancer Drugs Industry Restraints
3 Anticancer Drugs Market by Company
  1. 3.1 Global Anticancer Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Anticancer Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Anticancer Drugs Company Ranking (2024-2026)
  4. 3.4 Global Anticancer Drugs Company Manufacturing Base and Headquarters
  5. 3.5 Global Anticancer Drugs Company Product Type and Application
  6. 3.6 Global Anticancer Drugs Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Anticancer Drugs Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Anticancer Drugs Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Anticancer Drugs Market by Type
  1. 4.1 Anticancer Drugs Type Introduction
  2. 4.1.1 Cancer Immunotherapy
  3. 4.1.2 Chemotherapy
  4. 4.1.3 Targeted Therapy
  5. 4.1.4 Other
  6. 4.2 Global Anticancer Drugs Sales Value by Type
  7. 4.2.1 Global Anticancer Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Anticancer Drugs Sales Value by Type (2021-2032)
  9. 4.2.3 Global Anticancer Drugs Sales Value Share by Type (2021-2032)
5 Anticancer Drugs Market by Application
  1. 5.1 Anticancer Drugs Application Introduction
  2. 5.1.1 Blood-related Cancer
  3. 5.1.2 Breast Cancer
  4. 5.1.3 Prostate Cancer
  5. 5.1.4 Lung Cancer
  6. 5.1.5 Other
  7. 5.2 Global Anticancer Drugs Sales Value by Application
  8. 5.2.1 Global Anticancer Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Anticancer Drugs Sales Value by Application (2021-2032)
  10. 5.2.3 Global Anticancer Drugs Sales Value Share by Application (2021-2032)
6 Anticancer Drugs Regional Value Analysis
  1. 6.1 Global Anticancer Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Anticancer Drugs Sales Value by Region (2021-2032)
  3. 6.2.1 Global Anticancer Drugs Sales Value by Region: 2021-2026
  4. 6.2.2 Global Anticancer Drugs Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Anticancer Drugs Sales Value (2021-2032)
  7. 6.3.2 North America Anticancer Drugs Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Anticancer Drugs Sales Value (2021-2032)
  10. 6.4.2 Europe Anticancer Drugs Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Anticancer Drugs Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Anticancer Drugs Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Anticancer Drugs Sales Value (2021-2032)
  16. 6.6.2 South America Anticancer Drugs Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Anticancer Drugs Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Anticancer Drugs Sales Value Share by Country, 2025 VS 2032
7 Anticancer Drugs Country-level Value Analysis
  1. 7.1 Global Anticancer Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Anticancer Drugs Sales Value by Country (2021-2032)
  3. 7.2.1 Global Anticancer Drugs Sales Value by Country (2021-2026)
  4. 7.2.2 Global Anticancer Drugs Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Anticancer Drugs Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Anticancer Drugs Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Anticancer Drugs Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Anticancer Drugs Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Anticancer Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Anticancer Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Anticancer Drugs Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Anticancer Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Anticancer Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Anticancer Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Anticancer Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Anticancer Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Anticancer Drugs Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Anticancer Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Anticancer Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Anticancer Drugs Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Anticancer Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Anticancer Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Anticancer Drugs Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Anticancer Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Anticancer Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Anticancer Drugs Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Anticancer Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Anticancer Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Anticancer Drugs Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Anticancer Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Anticancer Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Anticancer Drugs Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Anticancer Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Anticancer Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Anticancer Drugs Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Anticancer Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Anticancer Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Anticancer Drugs Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Anticancer Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Anticancer Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Anticancer Drugs Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Anticancer Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Anticancer Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Anticancer Drugs Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Anticancer Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Anticancer Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Anticancer Drugs Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Anticancer Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Anticancer Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Anticancer Drugs Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Anticancer Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Anticancer Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Anticancer Drugs Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Anticancer Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Anticancer Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Anticancer Drugs Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Anticancer Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Anticancer Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Anticancer Drugs Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Anticancer Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Anticancer Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Anticancer Drugs Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Anticancer Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Anticancer Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Anticancer Drugs Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Anticancer Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Anticancer Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Anticancer Drugs Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Anticancer Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Anticancer Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Anticancer Drugs Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Anticancer Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Anticancer Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Anticancer Drugs Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Anticancer Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Anticancer Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Anticancer Drugs Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Anticancer Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Anticancer Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Anticancer Drugs Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Anticancer Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Anticancer Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Anticancer Drugs Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Anticancer Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Anticancer Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Anticancer Drugs Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Anticancer Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Anticancer Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda
  2. 8.1.1 Takeda Company Information
  3. 8.1.2 Takeda Business Overview
  4. 8.1.3 Takeda Anticancer Drugs Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Anticancer Drugs Product Portfolio
  6. 8.1.5 Takeda Recent Developments
  7. 8.2 Johnson & Johnson
  8. 8.2.1 Johnson & Johnson Company Information
  9. 8.2.2 Johnson & Johnson Business Overview
  10. 8.2.3 Johnson & Johnson Anticancer Drugs Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Johnson & Johnson Anticancer Drugs Product Portfolio
  12. 8.2.5 Johnson & Johnson Recent Developments
  13. 8.3 Novartis
  14. 8.3.1 Novartis Company Information
  15. 8.3.2 Novartis Business Overview
  16. 8.3.3 Novartis Anticancer Drugs Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Novartis Anticancer Drugs Product Portfolio
  18. 8.3.5 Novartis Recent Developments
  19. 8.4 Merck KGaA
  20. 8.4.1 Merck KGaA Company Information
  21. 8.4.2 Merck KGaA Business Overview
  22. 8.4.3 Merck KGaA Anticancer Drugs Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Merck KGaA Anticancer Drugs Product Portfolio
  24. 8.4.5 Merck KGaA Recent Developments
  25. 8.5 Roche
  26. 8.5.1 Roche Company Information
  27. 8.5.2 Roche Business Overview
  28. 8.5.3 Roche Anticancer Drugs Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Roche Anticancer Drugs Product Portfolio
  30. 8.5.5 Roche Recent Developments
  31. 8.6 Eli Lilly
  32. 8.6.1 Eli Lilly Company Information
  33. 8.6.2 Eli Lilly Business Overview
  34. 8.6.3 Eli Lilly Anticancer Drugs Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Eli Lilly Anticancer Drugs Product Portfolio
  36. 8.6.5 Eli Lilly Recent Developments
  37. 8.7 Gilead Sciences
  38. 8.7.1 Gilead Sciences Company Information
  39. 8.7.2 Gilead Sciences Business Overview
  40. 8.7.3 Gilead Sciences Anticancer Drugs Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Gilead Sciences Anticancer Drugs Product Portfolio
  42. 8.7.5 Gilead Sciences Recent Developments
  43. 8.8 Pfizer
  44. 8.8.1 Pfizer Company Information
  45. 8.8.2 Pfizer Business Overview
  46. 8.8.3 Pfizer Anticancer Drugs Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Pfizer Anticancer Drugs Product Portfolio
  48. 8.8.5 Pfizer Recent Developments
  49. 8.9 Hengrui Medicine
  50. 8.9.1 Hengrui Medicine Company Information
  51. 8.9.2 Hengrui Medicine Business Overview
  52. 8.9.3 Hengrui Medicine Anticancer Drugs Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Hengrui Medicine Anticancer Drugs Product Portfolio
  54. 8.9.5 Hengrui Medicine Recent Developments
  55. 8.10 GSK
  56. 8.10.1 GSK Company Information
  57. 8.10.2 GSK Business Overview
  58. 8.10.3 GSK Anticancer Drugs Revenue and Gross Margin (2021-2026)
  59. 8.10.4 GSK Anticancer Drugs Product Portfolio
  60. 8.10.5 GSK Recent Developments
  61. 8.11 Bristol-Myers Squibb
  62. 8.11.1 Bristol-Myers Squibb Company Information
  63. 8.11.2 Bristol-Myers Squibb Business Overview
  64. 8.11.3 Bristol-Myers Squibb Anticancer Drugs Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Bristol-Myers Squibb Anticancer Drugs Product Portfolio
  66. 8.11.5 Bristol-Myers Squibb Recent Developments
  67. 8.12 Amgen
  68. 8.12.1 Amgen Company Information
  69. 8.12.2 Amgen Business Overview
  70. 8.12.3 Amgen Anticancer Drugs Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Amgen Anticancer Drugs Product Portfolio
  72. 8.12.5 Amgen Recent Developments
  73. 8.13 AbbVie
  74. 8.13.1 AbbVie Company Information
  75. 8.13.2 AbbVie Business Overview
  76. 8.13.3 AbbVie Anticancer Drugs Revenue and Gross Margin (2021-2026)
  77. 8.13.4 AbbVie Anticancer Drugs Product Portfolio
  78. 8.13.5 AbbVie Recent Developments
  79. 8.14 AstraZeneca
  80. 8.14.1 AstraZeneca Company Information
  81. 8.14.2 AstraZeneca Business Overview
  82. 8.14.3 AstraZeneca Anticancer Drugs Revenue and Gross Margin (2021-2026)
  83. 8.14.4 AstraZeneca Anticancer Drugs Product Portfolio
  84. 8.14.5 AstraZeneca Recent Developments
  85. 8.15 Seagen
  86. 8.15.1 Seagen Company Information
  87. 8.15.2 Seagen Business Overview
  88. 8.15.3 Seagen Anticancer Drugs Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Seagen Anticancer Drugs Product Portfolio
  90. 8.15.5 Seagen Recent Developments
  91. 8.16 Regeneron
  92. 8.16.1 Regeneron Company Information
  93. 8.16.2 Regeneron Business Overview
  94. 8.16.3 Regeneron Anticancer Drugs Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Regeneron Anticancer Drugs Product Portfolio
  96. 8.16.5 Regeneron Recent Developments
  97. 8.17 Ono Pharmaceutical
  98. 8.17.1 Ono Pharmaceutical Company Information
  99. 8.17.2 Ono Pharmaceutical Business Overview
  100. 8.17.3 Ono Pharmaceutical Anticancer Drugs Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Ono Pharmaceutical Anticancer Drugs Product Portfolio
  102. 8.17.5 Ono Pharmaceutical Recent Developments
  103. 8.18 Merck & Co
  104. 8.18.1 Merck & Co Company Information
  105. 8.18.2 Merck & Co Business Overview
  106. 8.18.3 Merck & Co Anticancer Drugs Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Merck & Co Anticancer Drugs Product Portfolio
  108. 8.18.5 Merck & Co Recent Developments
  109. 8.19 Innovent
  110. 8.19.1 Innovent Company Information
  111. 8.19.2 Innovent Business Overview
  112. 8.19.3 Innovent Anticancer Drugs Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Innovent Anticancer Drugs Product Portfolio
  114. 8.19.5 Innovent Recent Developments
  115. 8.20 Exelixis
  116. 8.20.1 Exelixis Company Information
  117. 8.20.2 Exelixis Business Overview
  118. 8.20.3 Exelixis Anticancer Drugs Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Exelixis Anticancer Drugs Product Portfolio
  120. 8.20.5 Exelixis Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst